πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

127 results for β€œJin” Clear

  1. CAR-T Re-treatment

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  2. CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory B-cell Malignancies

    phase 1 mab active

    1 trial

  3. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  4. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  5. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  6. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  7. Hemay020

    Tianjin Hemay Pharmaceutical Co., Ltd

    Neoplasms，Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  8. LB1901

    Nanjing Legend Biotech Co.

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  9. LB1908

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab active

    1 trial

  10. LB2102

    Nanjing Legend Biotech Co.

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  11. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab terminated

    1 trial

  12. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  13. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Multiple Sclerosis (MS)

    phase 1 mab active

    1 trial

  14. LCAR-AIO cells product

    Nanjing Legend Biotech Co.

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

  15. LCAR-AMDR Cells Product

    Nanjing Legend Biotech Co.

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  16. LCAR-B4822M CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 1 small molecule active

    1 trial

  17. LCAR-BCDR cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab terminated

    1 trial

  18. LCAR-BCX cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  19. LCAR-C182A cells

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab terminated

    1 trial

  20. LCAR-C18S cells

    Nanjing Legend Biotech Co.

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  21. LCAR-G08 cells

    Nanjing Legend Biotech Co.

    Advanced Gastrointestinal Tumors

    phase 1 mab terminated

    1 trial

  22. LCAR-HL30 cells

    Nanjing Legend Biotech Co.

    Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  23. LCAR-M23 cells

    Nanjing Legend Biotech Co.

    Epithelial Ovarian Cancer

    phase 1 mab terminated

    1 trial

  24. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources